Navigation Links
CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
Date:2/14/2013

ONT-SIZE: 8pt"> shareholders – diluted

 

2,066 

2,488 

9,433 

11,354Diluted adjusted income per  common share, non-GAAP: 

0.08 

0.09 

0.34 

0.41Diluted-weighted average commonshares outstanding:27,35727,74527,41127,759 

Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP.  In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies.  Non-GAAP adjusted net income and adjusted income per common share exclude litigation expenses and benefits, insurance reimbursements for litigation, and expenses for business development activities, including the Company's transaction and integration costs primarily associated with the acquisitions of Hemosphere and Cardiogenesis.  The Company believes that this non-GAAP presentation provides useful information to investors regarding the operating expense structure of the Company's existing and recently acquired operations without regard to recently settled litigation, its ongoing efforts to acquire additional complementary products and businesses, and the transaction costs incurred in connection with recently acquired businesses.  The Company does, however, expect to incur similar types of business development expenses and may incur significant litigation expenses in the future, and this non-GAAP financial information should not be viewed as a promise or indication that these types of expenses will not recur.

 


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DIEGO , March 31, 2015 Neurocrine ... it has entered into an exclusive collaboration and licensing ... inhibitor, NBI-98854, in Japan and ... (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 ... associated with Huntington,s disease and tardive dyskinesia. Neurocrine retains ...
(Date:3/31/2015)... , March 31, 2015 UHC has ... the use of medical devices based on cost and ... physician preference items (PPIs). The study examined utilization of ... hospital,s supply expenses 1 —at 10 academic medical centers, ... stents, and cardiac valves. The study, ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 /PRNewswire/ ...  VSCI) today announced the completion of their merger. ... and completion of the all-stock combination creates a ... Beginning on April 1, 2015, Cogentix Medical, Inc. ... CGNT. Cogentix Medical will have its U.S. headquarters ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... Data,presented at the 2007 Annual Scientific Meeting of ... alli(R) (orlistat 60mg), the,only FDA- approved, over-the-counter (OTC) ... in helping them lose weight, and,not to potential ... data show that the weight loss achieved with ...
... Sanofi-aventis announced today,that the Japanese Ministry of ... for a Supplemental New Drug Application (sNDA) ... angina pectoris, non-ST elevation,myocardial infarction) for which ... Plavix(R) (clopidogrel). Approximately 100,000 patients develop ...
Cached Medicine Technology:Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 2Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Enterprise ... 501 Global Edition, a distinguished list and report ... (MSPs). The complete 501 list is currently available ... ,     The top ranked MSPs in North America ... East and Africa ,     The top MSPs ...
(Date:3/31/2015)... Every day a new diet fad is introduced in ... in other countries, and the diagnosis of American's with ... Natural Health Centers believe that by educating not only ... the future development of obesity and many other debilitating ... at no charge in their clinics. Because yo-yo and ...
(Date:3/31/2015)... Los Angeles, CA (PRWEB) March 31, 2015 ... the robotic hair transplant technique have yielded ... manual method , when refined and perfected by a ... results. While the most advanced techniques of hair restoration ... manual techniques can still be used to add precision ...
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:Beverly Hills Hair Transplant Surgeon Now Combines Advanced Robotic Hair Transplantation and Manual Techniques for Greatest Results 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3
... , , , , ... Field of Green Chemistry September 15 at UC Berkeley Campus ... Consumer concerns over hazardous chemicals in the air and water have ... chemistry. "The most troubling health effects are associated with endocrine disrupting ...
... will respond to cancer drug , TUESDAY, Sept. 8 (HealthDay ... certain aggressive cancers -- including those that attack the pancreas, ... drug. , The key appears to lie in a molecular ... issue of Nature Medicine . , Researchers at the ...
... agent lapatinib to delay tumor growth and improve the ... cancer, only benefited certain subgroups of patients. While results ... toxicity from the drug in the form of a ... and longer survival. Findings of this phase ...
... By investigating a rare and severe form of diabetes ... new molecular mechanism that regulates specialized pancreatic cells and ... which UI researchers previously linked to potentially fatal human ... this week in the Early Edition of the ...
... awarded a consortium of Chicago-based institutions, led by Rush ... a Developmental Center for AIDS Research, creating a comprehensive ... translational research in the prevention, detection and treatment of ... one of only two in the Midwest the ...
... MINNEAPOLIS/ST. PAUL (September 8, 2009)The Center for Infectious ... of Minnesota is convening an international summit on ... The summit will give business and health ... to protect employee health, critical operations and customer ...
Cached Medicine News:Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2Health News:Lapatinib shows minimal effect against liver cancer 2Health News:Lapatinib shows minimal effect against liver cancer 3Health News:Team reveals molecular mechanism underlying a form of diabetes 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 3Health News:U of M convenes a summit on the H1N1 influenza pandemic and critical business preparedness 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: